Identification and characterization of olanzapine degradation products under oxidative stress conditions

• Autorzy: Hiriyanna S. G. , Basavaiah K. , Goud P. S. K. , Dhayanithi V. , Raju K. , Pati H. N.
• Języki publikacji: EN

Abstrakty

EN

Studies of the degradation of olanzapine bulk drug under hydrolytic (acidic and alkaline), oxidising, and photolytic conditions are reported in this paper. Olanzapine is almost completely stable under photolytic and hydrolytic (acidic and alkaline) conditions. The major degradation products formed when olanzapine bulk drug was exposed to oxidative stress conditions were isolated by preparative reversed-phase highperformance liquid chromatography and characterized by FTIR, LC-MS-MS, and ¹H, ¹³C, and DEPT NMR. On the basis of results from spectroscopy the degradation products were characterized as 10-hydroxy-2-methyl-5,10-dihydro-4H-benzo[b]thieno [2,3- e][1,4]diazepin-4-one, 2-methyl-5,10-dihydro-4H-benzo[b]thieno[2,3-e][1,4]diazepin-4- one, and 2-methyl-10-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4] diazepin-4-yloxy)-5,10- dihydro-4H-benzo[b]thieno[2,3-e]diazepin-4-one. Identification, isolation, and characterization of these oxidative degradation products are discussed in detail.

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2008
• Tom: Vol. 20, no. 1
• Strony: 81--93
• Opis fizyczny: Bibliogr. 11 poz., rys., tab.

Twórcy

autor

Hiriyanna S. G.

autor

Basavaiah K.

autor

Goud P. S. K.

autor

Dhayanithi V.

autor

Raju K.

autor

Pati H. N.

• University of Mysore DOS in Chemistry Manasagangothri, Mysore 570006 India Peenya Industrial Area Process Chemistry Department, Advinus Therapeutics Bangalore 560058 India

Bibliografia

• [1] International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Stability Testing of New Drug Substances and Products. QIA (R2), August, 2003
• [2] International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Stability Testing: Photo Stability Testing of New Drug Substances and Products. QIB, January, 1998
• [3] S. Singh and M. Bakshi, Pharmaceutical Technology on-line, April, 2000
• [4] L.J. Dusei, L.P. Hackett, L.M. Fellows, and K.F. Ilett, J. Chromatogr. B, 774, 191 (2002)
• [5] O.V. Olesen and K. Linnet, J. Chromatogr. B, 714, 309 (1998)
• [6] J.A. Chiu and R.B. Franklin, J. Pharm. Biomed. Anal., 14, 609 (1996)
• [7] J.T. Catlow, R.D. Barton, M. Clemens, T.A. Gillespie, M. Goodwin, and S.P.Swanson, J. Chromatogr. B, 668, 85 (1999)
• [8] M.J. Bogusz, K.D. Kruger, R.D. Maier, R. Erkwoh, and F. Juchtenhagen, J. Chromatogr. B, 732, 257 (1999)
• [9] L.A. Larew, B.A. Olsen, J.D. Stafford, and M.V. Wilhelm, J. Chromatogr. A, 692, 183 (1995)
• [10] M.A. Raggi, G. Lasamenti, R. Mandroli, G. Izzo, and E. Kenndler, J. Pharm. Biomed. Anal. 23, 973 (2000)
• [11] S.W. Baertschi, H. Brunner, C.A. Bunnell, G.G. Cooke, B. Diseroad, D.E. Dorman, P.J. Jansen, C.A.J. Kemp, S.R. Maple, K.A. McCune, J.L. Speakman, J. Pharm. Sci. 97(2) 883–892 (2007).